Billionaire Mason Hawkins’ 10 Small-Cap Stocks with Huge Upside Potential

4. Bio-Rad Laboratories, Inc. (NYSE:BIO)

Market Capitalization: $6.80 billion

Number of Hedge Fund Holders: 42

Southeastern Asset Management Stake: $101,335,151

Analyst Upside Potential: 51.47%

Bio-Rad Laboratories, Inc. (NYSE:BIO) medical technology company that engages in developing and marketing a range of life science research and clinical diagnostic products. It operates through two main segments including the Life Science and Clinical Diagnostic segments. Its products range from testing kits to informatics systems and other key technologies such as chromatography, electrophoresis, flow cytometry, and more.

On April 2, RBC Capital analyst Conor McNamara maintained a Buy rating on the stock with a price target of $430. The company is focusing on enhancing its product portfolio. On February 13, Bio-Rad Laboratories, Inc. (NYSE:BIO) announced the acquisition of Stilla Technologies to enhance its digital PCR capabilities. Management noted that Stilla’s Nio dPCR systems complement existing QX Droplet Digital PCR and QX Continuum platforms, and will help broaden automation capabilities.

The company based softness in the fiscal fourth quarter of 2024. Its total revenue declined 2% year-over-year along with gross margins, which fell from 53.8% to 51.2%. To manage the losses Bio-Rad Laboratories, Inc. (NYSE:BIO) has decided to cut 5% of the workforce to save around $50 million to $55 million in 2025. Looking ahead, management anticipates 1.5% to 3.5% revenue growth in 2025. It is one of the billionaire Mason Hawkins’ 10 small-cap stocks with huge upside potential.